# A Study Investigating the Efficacy and Safety of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

> **NCT02247479** · PHASE3 · TERMINATED · sponsor: **Hoffmann-La Roche** · enrollment: 906 (actual)

## Conditions studied

- Geographic Atrophy

## Interventions

- **DRUG:** Lampalizumab
- **OTHER:** Sham

## Key facts

- **NCT ID:** NCT02247479
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-09-18
- **Primary completion:** 2018-01-29
- **Final completion:** 2018-01-29
- **Target enrollment:** 906 (ACTUAL)
- **Last updated:** 2019-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02247479

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02247479, "A Study Investigating the Efficacy and Safety of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02247479. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*